Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

ClinicalTrials.gov ID: NCT05092373

Public ClinicalTrials.gov record NCT05092373. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 10, 2026, 12:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID: NCT05092373
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: M.D. Anderson Cancer Center; Other
Enrollment: 43 participants

Conditions and interventions

Conditions

Interventions

Atezolizumab Biological
Cabozantinib S-malate Drug
Nab-paclitaxel Drug
Tumor Treating Fields Therapy Procedure

Biological · Drug · Procedure

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 28, 2022
Primary completion: Aug 31, 2026
Completion: Aug 31, 2026
Last update posted: Jan 13, 2026

2022 – 2026

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
M D Anderson Cancer Center	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05092373, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 13, 2026 · Synced May 10, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05092373 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →